Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yolanda Blanco

Showing results (101-110 of 156) with videos related to

Pageof 16
Sort By:
Journal of Neurology|February 14, 2019
Correction to: Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adultsAlvaro Cobo-Calvo, María Sepúlveda, Hyacintha d'Indy, et al.
Journal of Neurology|January 5, 2019
Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adultsAlvaro Cobo-Calvo, María Sepúlveda, Hyacintha d'Indy, et al.
JAMA Neurology|October 1, 2019
Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple SclerosisMagí Andorrà, Salut Alba-Arbalat, Anna Camos-Carreras, et al.
Journal of Neuroinflammation|July 4, 2019
Evaluation of treatment response in adults with relapsing MOG-Ab-associated diseaseAlvaro Cobo-Calvo, María Sepúlveda, Fabien Rollot, et al.
Frontiers in Neurology|March 24, 2023
Treatment of multiple sclerosis with rituximab: A Spanish multicenter experienceFrancisco Gascón-Giménez, Carmen Alcalá, Lluís Ramió-Torrentà, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 30, 2025
Cerebrospinal 14-3-3 Protein Levels as a Neuroaxonal Biomarker in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum DisorderJavier Villacieros-Álvarez, Maria Sepulveda, Adrián Valls-Carbó, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2019
Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trialIrati Zubizarreta, Georgina Flórez-Grau, Gemma Vila, et al.
Journal of Medical Genetics|November 20, 2012
Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosisAntonio Alcina, Maria Fedetz, Oscar Fernández, et al.
European Journal of Neurology|January 30, 2026
Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple SclerosisNicolás Fissolo, Pascal Benkert, Andreu Vilaseca-Jolonch, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2022
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registryTim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Pageof 16

Showing results (101-110 of 156) with videos related to

Sort By:
Pageof 16
Journal of Neurology|February 14, 2019
Correction to: Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adultsAlvaro Cobo-Calvo, María Sepúlveda, Hyacintha d'Indy, et al.
Journal of Neurology|January 5, 2019
Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adultsAlvaro Cobo-Calvo, María Sepúlveda, Hyacintha d'Indy, et al.
JAMA Neurology|October 1, 2019
Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple SclerosisMagí Andorrà, Salut Alba-Arbalat, Anna Camos-Carreras, et al.
Journal of Neuroinflammation|July 4, 2019
Evaluation of treatment response in adults with relapsing MOG-Ab-associated diseaseAlvaro Cobo-Calvo, María Sepúlveda, Fabien Rollot, et al.
Frontiers in Neurology|March 24, 2023
Treatment of multiple sclerosis with rituximab: A Spanish multicenter experienceFrancisco Gascón-Giménez, Carmen Alcalá, Lluís Ramió-Torrentà, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 30, 2025
Cerebrospinal 14-3-3 Protein Levels as a Neuroaxonal Biomarker in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum DisorderJavier Villacieros-Álvarez, Maria Sepulveda, Adrián Valls-Carbó, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2019
Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trialIrati Zubizarreta, Georgina Flórez-Grau, Gemma Vila, et al.
Journal of Medical Genetics|November 20, 2012
Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosisAntonio Alcina, Maria Fedetz, Oscar Fernández, et al.
European Journal of Neurology|January 30, 2026
Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple SclerosisNicolás Fissolo, Pascal Benkert, Andreu Vilaseca-Jolonch, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2022
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registryTim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Pageof 16